
Evolocumab was associated with a 20% lower risk of fatal or nonfatal myocardial infarction than ezetimibe among more than 544 000 adults with ASCVD.
A new 5-question COPD assessment tool may help identify more serious disease earlier in the primary care setting.
Obtaining a peak expiratory flow measurement and asking for a "yes" or "no" answer to 5 questions written at the 6th-grade reading level could help better identify patients with obstructive lung disease seen by primary care physicians who would most benefit from current therapies.






